04 Sep Bionova Scientific
Pratima Cherukuri, Ph.D., General Manager & Vice President of pDNA
Oct. 8 | 11:30am | FLW Ballroom F
Houston, TX
(Private)
Bionova Scientific®, a commercial-scale biologics CDMO and proud member of the Asahi Kasei Group, partners with innovators to bring life-changing therapies to market with a strong commitment to quality and service. Founded in 2014 and acquired by Asahi Kasei in 2022, Bionova provides advanced technology platforms and scientific expertise across the full drug development lifecycle.
As an integrated CDMO, Bionova offers end-to-end services from discovery through cGMP commercial supply of complex therapeutic proteins and antibodies. Backed by a team of seasoned scientists with decades of experience, we help clients overcome early development challenges and accelerate programs from discovery to first-in-human studies with scalable, efficient solutions.
In 2025, Bionova expanded with a dedicated plasmid DNA (pDNA) development and manufacturing facility in Houston, Texas. With state-of-the-art facilities in Houston and the San Francisco Bay Area, Bionova remains a flexible, collaborative, and quality-focused partner for advanced therapy production.
